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The relative resistance of human immunodeficiency virus type 1 (HIV-1) primary isolates (PIs) to neutral-
ization by a wide range of antibodies remains a theoretical and practical barrier to the development of an
effective HIV vaccine. One model to account for the differential neutralization sensitivity between Pls and
laboratory (or T-cell line-adapted [TCLA]) strains of HIV suggests that the envelope protein (Env) complex is
made more accessible to antibody binding as a consequence of adaptation to growth in established cell lines.
Here, we revisit this question using genetically related PI and TCLA viruses and molecularly cloned env genes.
By using complementary techniques of flow cytometry and virion binding assays, we show that monoclonal
antibodies targeting the V3 loop, CD4-binding site, CD4-induced determinant of gp120, or the ectodomain of
gp41 bind equally well to PI and TCLA Env complexes, despite large differences in neutralization outcome. The
data suggest that the differential neutralization sensitivity of PI and TCLA viruses may derive not from
differences in the initial antibody binding event but rather from differences in the subsequent functioning of
the PI and TCLA Envs during virus entry. An understanding of these as yet undefined differences may enhance
our ability to generate broadly neutralizing HIV vaccine immunogens.
Adaptation of a primary isolate (PI) of human immunode-
ficiency virus type 1 (HIV-1) to persistent growth in established
T-cell lines is accompanied by genetic changes in the virus.
Because PI viruses are isolated in primary T-lymphocyte cul-
ture, and for the most part are unable to productively infect
established T-cell lines, powerful selection pressures are exert-
ed upon the PI virus population to obtain variants which grow
in T-cell lines. Changes in the viral envelope protein (Env)
mediate many of these adaptations (65), although additional
changes also affect postentry events. For instance, changes in
viral Vpr alter cell cycle control to facilitate persistent growth
in continually dividing cell lines (52).
Remarkably, changes in Env that mediate the expanded cell
tropism for established T-cell lines also mediate changes in
neutralization sensitivity: T-cell line-adapted (TCLA) isolates
display increased sensitivity to neutralization by soluble forms
of CD4 (sCD4) and by antibodies. This general conclusion
comes from numerous cross-sectional comparisons of PI and
TCLA viruses, but most convincingly from longitudinal com-
parisons of the neutralization sensitivity of PI viruses and their
derivative TCLA strains (2, 16, 34, 64, 65, 67).
It is this observation of differential neutralization sensitivity
that drives the study of T-cell line adaptation. Initial efforts to
develop sCD4 for antiviral therapy were thwarted in part by
the unexpected resistance to inhibition of PI viruses relative to
the TCLA viruses commonly used in earlier studies (10, 11).
This differential sensitivity to neutralization again attracted
widespread attention in 1993 when it was found that PI viruses
were refractory to antibodies elicited by recombinant gp120
vaccine immunogens, antibodies that potently neutralize the
infectivity of TCLA viruses (9).
Several theories have been advanced to account for the
coincident changes in cell tropism and neutralization sensitiv-
ity. Most models suggest that adaptation to growth in T-cell
lines involves a facilitation of the initial viral interactions with
the cell in order to allow rapid infection in culture and that this
facilitation is accomplished through an “opening up” of the
trimeric Env complex structure (36). For example, the CD4-
binding site of the TCLA Env complex might become relatively
more accessible to CD4 binding. This accessibility to cell bind-
ing events would carry over to a similar accessibility, and vul-
nerability, to neutralizing antibodies. According to this model,
the resistance of PI viruses to neutralization derives from rel-
ative constraints (either steric or dynamic) on antibody binding
to the oligomeric Env complex. In fact, several studies have
reported differential binding of specific monoclonal antibodies
(MAbs) to TCLA versus PI virions and cell surface Envs (4, 56,
57). These studies have compared binding to genetically unre-
lated PI and TCLA Envs and to Envs that differ significantly at
the local MAb binding site. By contrast, we have previously
reported equal binding of MAbs to cells infected with geneti-
cally related PI and TCLA viruses (65). In other studies, we
(42, 43, 68) have demonstrated specific MAb binding to intact
and infectious PI virions in the absence of neutralization.
In this report, we revisit the fundamental question: is the
differential sensitivity to neutralization of PI and TCLA viruses
due to differential antibody binding? We examine the ques-
tion of antibody binding using two pairs of PI and derivative
TCLA viruses. Using three independent and complementary
methods, we find equal binding of monoclonal antibodies to
neutralization-resistant PI viruses and their neutralization-sen-
sitive TCLA virus derivatives. Therefore, the differential sen-
sitivity of PI and TCLA viruses to neutralization does not arise
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upon initial antibody binding, but rather reflects differences in
downstream events within the functioning PI and TCLA Envs.
Our results suggest that a full understanding of virus neutral-
ization and the differential sensitivity of PI and TCLA viruses
will require an examination of the dynamic processes whereby
the HIV Env mediates virus binding and entry.
MATERIALS AND METHODS
Viruses and molecularly cloned env expression plasmids. The derivation and
characterization of TCLA viruses 168C and 320SI-C3.3 and the respective pa-
rental PI viruses 168P and 320SI, have been previously described (see Table 1).
Virus stocks were prepared either from acutely infected H9 cell culture (TCLA
viruses) or from primary T-lymphocyte culture (PI viruses). It should be noted
that these TCLA viruses remain neutralization sensitive and otherwise unaltered
when prepared from primary T-lymphocyte culture (65; K. E. Follis and J. H.
Nunberg, unpublished). The relative amount of Env per virion (gp 120 to p24)
was determined by Western blot analysis of pelleted virions (56, 64) with either
an anti-gp 120 MAb or pooled immunoglobulin (Ig) from HIV-infected persons
(HIVIG) to detect gp120 or p24, respectively. The signals were quantified using
ECL-Plus (Amersham Pharmacia Biotech) and a Fuji FLA-3000G analyzer, and
the ratio of gp120 to p24 fluorescence was determined. Virus neutralization
assays were performed with 96-well microculture as previously described (16, 28).
For this assay, serial dilutions of antibody are incubated with a predetermined
amount of virus for 1 h at 37°C, and this mixture is then incubated with U87-
CD4-CXCR4 cells (23) for 2 days to allow the expression of HIV proteins.
Infected cells (foci) are detected by immunochemical staining with either HIVIG
or biotinylated anti-gp120 MAb 50.1 (Repligen Corp.). Similar neutralization
results are obtained, for permissive viruses, by using U87-CD4-CCR5 cells (16,
28).
High-fidelity XL PCR (rTth and Vent DNA polymerases; PE Applied Bio-
systems) and oligonucleotide primers envA and envN (18) were used to amplify
proviral DNA carrying rev and env genes. All amplifications were from DNA of
infected cells, except that 320SI env was isolated from an infectious molecularly
cloned provirus, ACH320.2A.1.2, provided by Hanneke Schuitemaker (Central
Laboratory of the Netherlands Red Cross) through the NIBSC AIDS Reagent
Project (Herts, United Kingdom). PCR products were isolated by unidirectional
T/A cloning with the eucaryotic expression vector pCR3.1-Uni (Invitrogen). In
all cases, the molecularly cloned TCLA env genes chosen for analysis encode the
same adaptation-related amino acid changes as the virus population and reca-
pitulate coreceptor use and neutralization sensitivity phenotypes (16, 28, 65).
The specific 168P23 and 168C23 env genes chosen (GenBank accession numbers
AF035532 and AF035534, respectively) also differ at random positions unrelated
to neutralization sensitivity: gp120 C1 A62V, V1 V150M, V2 K164T, gp41
ectodomain A562T, H587Y, and cytoplasmic domain N810S (28; M. Trahey and
J. H. Nunberg, unpublished). The human CD4 cDNA was obtained from R. Axel
(through the NIH AIDS Research and Reference Reagent Program) and was
subcloned for expression in pcDNA3.11 (Invitrogen). Green fluorescent protein
(GFP) was expressed using the pEGFP-N1 plasmid from Clontech Laboratories,
Inc.
Antibodies and related reagents. MAbs used in these studies are described in
Table 2 and were generously provided as indicated. HIVIG was provided by A.
Prince (New York Blood Center), and sCD4 was purchased from Progenics
Corp. Cellular CD4 was detected in flow cytometry with MAB 379 (R&D
Systems) or the non-gp120-competing MAb HCD4-A6 (Devaron, Inc.).
Transfection protocol and analysis of expressed proteins. FuGENE-6 reagent
(Roche Molecular Biochemicals) was used to transfect simian COS-7 cells
(American Type Culture Collection) for transient expression. In a typical exper-
iment, 0.8 mg of GFP-expressing plasmid was mixed with 15.2 mg of Env- or
CD4-expressing plasmid and applied (with 48 ml of FuGENE-6 reagent in 800 ml
of Dulbecco’s Modified Eagle Medium [DMEM; Gibco BRL]) to 106 COS-7
cells in a 10-cm-diameter culture dish in 10 ml of DMEM with 10% fetal bovine
serum (FBS). Transfected cultures were washed 16 to 18 h later and refed with
10 ml of DMEM with 10% FBS. Transfection efficiencies were determined for
Envs by immunochemical staining of cold methanol:acetone (1:1)-fixed mono-
layers using HIVIG with alkaline phosphate-conjugated goat anti-human IgG
antibody (Kirkegaard & Perry Lab.) and PhThalo Red chromogen (Kirkegaard
& Perry Lab.) or, for CD4 and GFP, by flow cytometry. Env expression was also
assessed by Western blot analysis of cell surface proteins. Cells were biotinylated
using NHS-LC-biotin (Pierce Chemical) (31) and lysed on ice in 50 mM Tris (pH
7.5), 150 mM NaCl, and 1% Triton X-100 containing 1 mg each of aprotinin,
leupeptin, and pepstatin per ml. Env was immunoprecipitated using 5 mg of
HIVIG and protein A-Sepharose (Sigma). Western blot analysis utilized avidin-
horseradish peroxidase conjugate (Biomeda) and ECL-Plus detection.
Flow cytometry. COS-7 cells were used in flow cytometry 40 h after FuGENE-
6-mediated cotransfection with GFP and env plasmids. Parallel cultures were
cotransfected with GFP and CD4 plasmids to assess nonspecific antibody binding
and autofluorescence. For analysis, transfected cell cultures were resuspended
using 0.1 mM EDTA in phosphate-buffered saline (PBS). A total of 2 3 105 cells
were stained with HIVIG or Env-specific MAbs at 4°C for 20 min in 100 ml of
PBS containing 2% FBS and 0.05% sodium azide. Specific MAbs are described
in Table 2, and the concentration of each MAb used to assess binding to
neutralization-sensitive TCLA Envs and neutralization-resistant PI Envs is listed
in the legend to Fig. 3. MAb binding was detected by using either biotinylated
anti-mouse IgG or biotinylated anti-human IgG antibody (Jackson ImmunoRe-
search Laboratories), followed by the use of streptavidin-CyChrome conjugate
(PharMingen). Cells were analyzed with a Becton Dickinson FACSCalibur and
CELLQuest software (Becton Dickinson Immunocytometry Systems). A double
gate was defined by forward versus side scatter and by forward scatter versus the
amount of GFP (FL-1). A total of 5,000 events within this gate were collected for
analysis. CyChrome-labeled cells were detected in FL-3, and mean fluorescence
intensity was determined as mean fluorescence channel (MFC) (CELLQuest).
Nonspecific fluorescence, as measured in identically stained CD4- and GFP-
cotransfected cells, occupied only the lowest fluorescence channels and was
removed using histogram subtraction software (CELLQuest).
Quantum PE-Cy5 beads (Flow Cytometry Standards Corp., San Juan, P.R.)
were used to convert CyChrome fluorescence intensity to numbers of fluoro-
phores/cell (molecules of equivalent soluble fluorophore). At the instrument
TABLE 1. Pedigreed PI and TCLA virusesa
Virus Isolate type Coreceptor(s) used Central V3 loop Adaptation-associated aa changes Reference(s)
168P PI CCR5 and CXCR4 NIRKRIHIGPGRAFYTTG 28, 65
168C TCLA CXCR4 NIRKRIHIGPGRAFYTTR V2 I166R, C2 I282N, and V3 G318R
320SI PI CCR5 and CXCR4 NTRKGIHIGPGRAFYAAR 16
320SI-C3.3 TCLA CCR5 and CXCR4 NTRKGIRIGPGRAFYAAR V2 I166K and V3 H317R
a Amino acid (aa) changes in the central V3 loop of the TCLA virus are underlined.
TABLE 2. Env-directed MAbsa
Anti-
body Target Nominal epitope
b Source Refer-ence
50.1 V3 loop ....RIHIG......... Repligen Corp. 63
58.2 V3 loop .......IGPGRAF.... Repligen Corp. 63
59.1 V3 loop ........GPGRAF.... Repligen Corp. 63
257-D V3 loop ...KRIHI.......... S. Zolla-Pazner 19
268-D V3 loop ......HIGPGR...... S. Zolla-Pazner 19
447-52D V3 loop ........GPGR...... S. Zolla-Pazner 19
IgG1b12 CD4-bs D. Burton, from ARRRP 5
559-64D CD4-bs S. Zolla-Pazner 25
F105 CD4-bs M. Posner 50
17b CD4-i See reference 27 J. Robinson 60
2F5 gp41 gp41...ELDKWA H. Katinger 40
F240 gp41 gp41...aa 592–606 M. Posner 7
a CD4-bs, CD4-binding site; CD4-i, CD4 induced; aa, amino acids; ARRRP,
NIH AIDS Research and Reference Reagent Program.
b Nominal MAb epitopes are reported in the associated references. Central V3
loop epitopes are arrayed as in Table 1.
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settings used in our measurements, we determined a linear relationship: log10
(MFC) 5 [0.811 3 log10 (molecules of equivalent soluble fluorophore)] 2 2.072.
Virion capture assays. MAb binding to intact virions was measured using a
virion capture enzyme-linked immunosorbent assay (ELISA) as previously de-
scribed (42, 43). Virus stocks were comprised of cleared cell culture superna-
tants, and captured HIV p24 core protein was quantitated by a separate p24 an-
tigen capture ELISA (Coulter). All comparisons of PI versus TCLA virus binding
were normalized using HIVIG as a nondiscriminating virion capture reagent.
The infectivity of MAb-captured virions was determined in a different format
using MAb-coated magnetic beads (Dynal A.S., Oslo, Norway). Streptavidin-
coated M-280 DynaBeads were saturated with biotinylated MAb 50.1 in PBS
containing 2% FBS or incubated with an equal amount of non-biotinylated MAb
50.1 as a control. For virion capture studies, 0.5 mg of beads (containing ap-
proximately 2 mg of biotinylated MAb) was incubated with 168P or 168C virus
stocks (containing approximately 200 ng of gp 120). Incubations were carried out
with intermittent mixing for 2 h at either 4 or 37°C. The magnetic beads were
subsequently washed three times in PBS–2% FBS at 4°C and were then serially
diluted onto U87-CD4-CXCR4 cells to assess retained infectivity. Microcultures
were rinsed after 2 days of culture, and infected cells were immunochemically
stained using HIVIG.
RESULTS
Cross-sectional comparisons of neutralization sensitivity in
unrelated PI and TCLA viruses can be confounded by un-
known immunochemical differences between genetically dis-
parate viruses. Therefore, we and others (2, 16, 65, 67) have
focused on the analysis of pedigreed PI and TCLA viruses, i.e.,
TCLA viruses derived by stringent adaptation of PI viruses to
persistent growth in initially restrictive T-cell lines. We have
previously described two pairs of pedigreed PI and TCLA vi-
ruses (Table 1); our present studies of MAb binding initially
examined one of these pairs, 168P and 168C.
The dual-coreceptor-utilizing PI virus 168P (ACH168.10)
(12, 59) had been adapted to persistent growth in the H9 T-cell
line (65). The resulting TCLA 168C env displays a marked
preference for use of the CXCR4 (versus CCR5) coreceptor
and encodes three adaptation-related amino acid changes (in
the V2 loop, C2 domain, and V3 loop) (Table 1), each of which
is required for full neutralization sensitivity (Trahey and Nun-
berg, unpublished). In an earlier study (65), the question of
MAb binding to primary T lymphocytes infected with either
168P or 168C was examined, but the interpretation of these
studies was confounded by the possibility that binding may have
also been to monomeric gp120 that was shed and then cap-
tured by cellular CD4, rather than to an authentic cell-associ-
ated Env complex. Here, we addressed this question utilizing
molecularly cloned 168P and 168C env genes expressed on the
surface of CD4-negative COS-7 cells. The molecularly cloned
env genes (168P23 and 168C23) encode functional Envs that
recapitulate the neutralization and coreceptor phenotypes of
the original PI and TCLA virus populations (28). Our initial
flow cytometric efforts to quantitate antibody binding to Env
on transiently-transfected COS-7 cells were limited, however,
by the overlap between the specific fluorescence from trans-
fected cells and the background autofluorescence from non-
transfected cells in the population. The resulting “shoulder” of
MAb binding makes quantitation problematic.
Flow cytometric analysis of MAb binding. To separate this
background from authentic binding to Env-expressing cells, we
developed a strategy in which transfected cells could be ana-
lyzed in isolation from nontransfected cells. COS-7 cells were
cotransfected with a plasmid expressing GFP and an excess of
plasmid expressing Env. We were then able, by flow cytometry,
to focus our analysis on GFP-positive cells and thus were able
to greatly enrich for cells that also expressed Env. The ratio of
Env- to GFP-expressing plasmids (20:1) was optimized such
that ,95% of GFP-positive cells were also Env positive.
Residual background and autofluorescence were deter-
mined from binding to cells cotransfected with CD4 and GFP
plasmids (20:1); background was uniformly faint and subtrac-
tion had little effect on measurements of specific MAb binding.
Clear and symmetric binding histograms were obtained us-
ing the GFP cotransfection method (e.g., Fig. 1 and 2). Spe-
cific antibody binding was quantified using MFC calculations.
These determinations of binding were robust and largely inde-
pendent of transfection parameters, specific GFP-gating choices,
or background subtraction. In replicate measures of antibody
FIG. 1. HIVIG as a nondiscriminating measure of Env expression. COS-7 cells were transfected to express GFP and either 168P Env or 168C
Env as described in Materials and Methods. (A) Flow cytometric analysis of HIVIG staining of GFP-positive cells expressing either 168P Env (dark
line) or 168C Env (light line). (B) Transfected cultures were biotinylated on the cell surface with NHS-LC-biotin reagent (Pierce), and Env was
immunoprecipitated with HIVIG and detected by Western blot analysis using avidin-horseradish peroxidase conjugate. Transfection efficiency was
determined by immunochemical staining of fixed monolayers using HIVIG; the percentage of cells stained by HIVIG is indicated.
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binding, MFC values were consistently within 20%. Fluores-
cent bead standards (Flow Cytometry Standards Corp.) were
used to convert MFC values to relative numbers of bound
antibody molecules (see Materials and Methods). At the in-
strument settings used in our antibody binding studies and
within the range of typical MFC measurements, and experi-
mental variation of 20% in MFC translates roughly to a 20%
variation in the determined number of bound antibody mole-
cules. Specifically, if there were to be a 10-fold reduction in the
binding of antibody to PI (versus TCLA) Env, then this would
be reflected in a 7-fold reduction in MFC (see Materials and
Methods). The sensitivity of this flow cytometric method is
more than sufficient to detect binding differences that ap-
proach the differences observed in neutralization sensitivity.
In most experiments, transfection efficiencies and Env ex-
pression levels were similar for PI and TCLA env plasmids.
Cell surface Env expression levels were normalized by flow
cytometry using HIVIG as a generic polyclonal reagent that we
presumed did not discriminate markedly in binding between PI
and TCLA Envs (Fig. 1A). This presumption was confirmed by
Western blot analysis of immunoprecipitable Env from deter-
gent lysates of transfected cell cultures (Fig. 1B). This method
provides a known nondiscriminatory measure of Env (35) and
the concordance among the immunochemical measurement of
solubilized monomeric Env, the transfection efficiency, and the
flow cytometric analysis of cell-surface Env complex confirmed
that HIVIG can be used as a nondiscriminating measure of cell
surface PI and TCLA Env expression. Thus, we were able to
normalize MFC values across MAb binding studies of inde-
pendently transfected PI and TCLA Env-expressing cell cul-
tures. Given that PI and TCLA Env expression levels were
generally comparable in our studies (see the legend to Fig. 3),
normalization had little effect on relative binding values to PI
and TCLA Envs.
Note also that proteolytic processing of gp160 was incom-
plete in these transfected cells (Fig. 1B) and that only approx-
imately 25% of cell surface Env was present as mature gp120.
The relative extent of processing was, however, comparable
between the PI and TCLA Envs. The extent of gp160 cleavage
was not appreciably enhanced by coexpression of furin, one of
several Golgi-associated proteases that have been implicated
2744 YORK ET AL. J. VIROL.
in Env processing (22) and one that has been shown to effec-
tively process secreted gp140 (3).
MAb binding to 168P and 168C Envs. Using this flow cyto-
metric method, we examined the binding of MAbs directed to
key Env targets: the V3 loop, the CD4-binding site, the CD4-
induced determinant of gp120, and the ectodomain of gp41
(Table 2). These targets were chosen because they are well-
mapped and well-defined neutralizing determinants of TCLA
viruses and because they have been suggested to be relatively
inaccessible on the PI virus Env complex.
To ensure that MAb binding was assessed at a concentration
that is functionally relevant and informative, the neutralization
sensitivities of 168P and 168C viruses were determined for
each MAb reagent used (Fig. 2A, C, E, and G). In all cases,
this PI virus was largely refractory to neutralization. A MAb
concentration that clearly distinguished between the neutral-
ization-resistant PI virus and the neutralization-sensitive
TCLA virus was chosen (where possible) for flow cytometric
binding analysis. In some cases, neutralization of the PI and
FIG. 2. Flow cytometric analysis of MAb binding to 168P and 168C
Envs. (A, C, E, and G) Neutralization sensitivity of 168P (dark line)
and 168C (light line) viruses to the indicated MAbs was determined
using U87-CD4-CXCR4 cells as described in Materials and Methods.
Infected cells (foci) were determined by microscopic analysis of im-
munochemically stained monolayers, and the number of foci was com-
pared to that obtained in the absence of MAb. (B, D, F, and H) COS-7
cells were transfected to express GFP and either 168P Env or 168C
Env as described in Materials and Methods. Flow cytometric analysis
of MAb binding to GFP-positive cells expressing either 168P Env (dark
line) or 168C Env (light line) is illustrated. MAbs were used at the
discriminating concentrations determined by neutralization as indi-
cated in the legend to Fig. 3.
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TCLA viruses differed by over 20-fold at the concentrations
used (e.g., MAbs 50.1, 58.2, 257-D, 268-D, 447-52D, and 559-
64D). Thus, we were able to obtain accurate flow cytometric
quantitation of binding to PI and TCLA Envs at a concentra-
tion of MAb that yields dramatically different outcomes in
neutralization (Fig. 2B, D, F, and H). A summary comparing
MAb binding to 168P PI and 168C TCLA virus Envs is pre-
sented in Fig. 3. In all cases, Env-specific MAbs, regardless of
specificity, bound equally to neutralization-resistant PI Env
and neutralization-sensitive TCLA Env.
One potential variable in studies of gp120-binding MAbs
relates to the relative ease with which gp120 can be shed from
the cell surface Env complex (38). This same concern may
apply, but in reverse, to the binding of gp41-directed MAbs.
Although significant amounts of gp120 were found to accumu-
late in 24-h culture supernatants of cells expressing either 168P
or 168C Env, we did not detect loss of gp120 during the short
4°C incubations used in these studies. Comparable amounts of
gp120 and gp41 were detected by flow cytometry with cells
regardless of prior incubation, including incubation in the pres-
ence of sCD4 (data not shown). Thus, gp120 shedding and/or
exposure of gp41 was not a confounding variable in the present
studies.
The single amino acid change in the V3 loop of 168C did not
appear to affect binding to distal epitopes of the V3 MAbs.
Although the specific targets for some of the non-V3-directed
MAbs are less well defined, it should be remembered that 168P
and 168C Envs are very nearly identical in sequence. The slight
reduction in sCD4 binding to 168C (Fig. 2H) may be attribut-
able to the amino acid change in the C2 domain near the
CD4-binding pocket (I282N) (27), but this difference in sCD4
binding is not seen in the comparison of other PI and TCLA
viruses (Fig. 4).
In this regard, it is also interesting to note the binding of
MAb 17b. This epitope is enhanced upon sCD4 binding (61)
and is thought to reflect conformational changes that parallel
those within the functioning Env. Based on structural and
mutagenic analysis, this site is believed to define an Env inter-
face critical for subsequent binding to a coreceptor (51). In our
studies, the level of binding of MAb 17b to 168C was somewhat
greater than to 168P (Fig. 3), although this difference between
PI and TCLA Envs was not seen in other PI and TCLA viruses
(Fig. 4 and reference 58). If PI and TCLA Envs differ markedly
FIG. 3. Summary of MAb binding to 168P and 168C Envs. MAb
binding was determined by flow cytometry as described in Materials
and Methods and quantitated using MFC computation (CELLQuest
software). The respective MFC values for binding to 168P and 168C
Envs were normalized relative to HIVIG binding to account for mod-
est differences in Env expression. The normalized values for MAb
binding to 168P and 168C Envs are plotted. Among all experiments,
MFC values for HIVIG binding to 168P and 168C Envs were 70 6 35
and 67 6 28, respectively. The ratio of HIVIG MFC values within any
experiment (1.07 6 0.39) was also consistent with the ratio of trans-
fection efficiencies (1.01 6 0.13). Representative MAb binding values
compared within one experiment are shown. Purified MAbs were used
at a concentration of 10 mg/ml (except for MAbs 58.2 and 59.1, which
were used as a 1:100 dilution of ascites fluids), and sCD4 was used at
a concentration of 50 mg/ml. At these concentrations, the relative
amounts of neutralization of 168P and 168C, respectively, are shown in
parentheses (as percentages); few if any of the antibody reagents
significantly neutralized 168P. Symbols: , 50.1 (0, 95); Q, 58.2 (55, 99);
, 59.1 (20, 70); E, 257-D (50, 97); , 268-D (50, 95); F, 447-52D (75,
99); , 559-64D (45, 95); , IgGb12 (25, 55); }, F105 (30, 65); Œ, 17b
(30, 80); ‚, sCD4 plus 17b (not applicable); ■, 2F5 (60, 75); h, F240
(0, 0); , sCD4 (80, 99 at 10 mg/ml).
FIG. 4. Summary of MAb binding to 320SI and 320SI-C3.3 Envs.
Methods and MAb concentrations are as described in the legend to
Fig. 3. At these concentrations, the relative amounts of neutralization
of 320SI and 320SI-C3.3, respectively, are shown in parentheses (as
percentages); none of the antibody reagents significantly neutralized
320SI. Symbols: , 50.1 (0, 45); !, 58.2 (10, 70); , 59.1 (15, 70); G,
257-D (0, 60); , 268-D (0, 0); F, 447-52D (2, 95); , 559-64D (20, 30);
{, lgGb12 (25, 99); }, F105 (10, 70); Œ, 17b (10, 60); ‚, sCD4 plus 17b
(not applicable); ■, 2F5 (40, 99); h, F240 (0, 0); , sCD4 (0, 99 at 10
mg/ml). The mean ratio of HIVIG MFC values for 320SI and 320SI-
C3.3 Envs was 0.87 6 0.21, and these values varied among experiments
similarly to those of 168P and 168C.
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in their ability to bind MAb 17b or to undergo the CD4-
induced conformational changes that enhance MAb 17b bind-
ing, then it was not apparent in these studies.
MAb binding to a second pair of PI and TCLA viruses.
We sought to extend these findings using an additional pair
of pedigreed PI and TCLA viruses. We had previously de-
scribed the functional and genetic changes that accompa-
nied T-cell line adaptation of the molecularly cloned PI virus
320SI (ACH320.2A.1.2) (20, 21). The env gene of the resulting
TCLA virus 320SI-C3.3 encodes two adaptation-related amino
acid changes (in the V2 and V3 loops; Table 1), and this TCLA
Env continues to utilize both CCR5 and CXCR4 coreceptors
(16). For the present study, the env genes of 320SI and 320Sl-
C3.3 were molecularly cloned using PCR and envA and envN
oligonucleotide primers as previously described (28). DNA
sequence analysis confirmed the adaptation-associated amino
acid changes originally noted in the virus population.
Flow cytometric analysis of binding to GFP-cotransfected
cells expressing either 320Sl or 320Sl-C3.3 Env is summarized
in Fig. 4. Again, specific MAb binding to the neutralization-
resistant PI and neutralization-sensitive TCLA Envs was equal.
The sole exception is of interest: MAb 268-D recognizes the
nominal epitope HIGPGR (19), which is present on the PI Env
but is altered to RIGPGR on the TCLA Env. The observed
binding of MAb 268-D to the PI Env and not to the TCLA Env
highlights the specificity of the flow cytometric analysis. Other
nominal MAb epitopes, such as those of MAbs 50.1 and 257-D,
were not entirely predictive of binding to the native Env pro-
tein, as has been demonstrated previously (42). Binding of
these MAbs to sequences that differ from the nominal
epitope (Tables 1 and 2) was detected under saturating
conditions, but neutralization potency against the 320SI-C3.3
TCLA virus was clearly reduced relative to, e.g., 168C (see the
legend to Fig. 3 and 4). In contrast to what has been observed
as sCD4-induced enhancement of MAb 17b binding to other
Envs, and to 168P and 168C Envs, sCD4 did not appreciably
increase binding of MAb 17b to either 320SI or 320SI-C3.3
Env. This result cannot be attributed to differential sCD4-
induced gp120 shedding as, again, we could not detect signif-
icant loss of gp120 during incubation at 4°C (data not shown).
Because temperature can play a major role in Env dynamics
and interactions (13, 17, 37, 55), we examined whether differ-
ences in MAb binding to PI and TCLA Envs might be observed
if incubations were performed at physiological temperatures.
These efforts were confounded, however, by significant albeit
inconsistent losses of membrane proteins, despite the addition
of up to 0.2% sodium azide. The loss was not limited to gp120
but included comparable losses in integral membrane proteins
such as gp41 and CD4 and occurred in the absence of MAb or
sCD4 (data not shown). We presume that these losses reflect
membrane blebbing and recycling within the culture (32);
much of the membrane protein lost from the GFP-positive cell
population at 37°C can be accounted for as a generalized
increase in staining of the GFP-negative cell population. Any
measure of gp120 shedding at 37°C is confounded by the gen-
eral loss of membrane proteins. Despite these technical diffi-
culties in quantitation, we could detect no systematic differ-
ences in MAb binding to PI (168P or 320SI) versus TCLA
(168C or 320SI.C3.3) Envs in any experiment in which MAb or
sCD4 was bound at either 22 or 37°C (data not shown). Al-
though the extension of our flow cytometric studies to physi-
ological temperature conditions must remain preliminary, our
findings consistently suggest that the extent of MAb binding to
PI and TCLA Envs is also equal at 37°C.
MAb binding to intact and infectious PI and TCLA virions.
The studies described above utilized molecularly cloned Envs
expressed on the surface of transfected cells. These Envs are
fully functional in mediating cell-cell fusion and recapitulate
the neutralization and coreceptor phenotypes of the parent
virus population (16, 28). We presume that these Envs are
presented on the cell surface much as on HIV virions. How-
ever, the high level of Env production during transient expres-
sion also results in the accumulation of unprocessed gp160 on
the cell surface (Fig. 1B), presumably due to saturation of the
cellular proteolytic machinery. In actual HIV infection, these
immature gp160 molecules are also present but are possibly
excluded from the budding virion (14). The structure of the
virion Env may also be modified by interaction with virion core
proteins (15). Therefore, we wished to confirm our findings of
equal binding to PI and TCLA Envs with authentic virion
particles. For these studies, we utilized a virion capture ELISA
(45) that had previously been used to assess MAb binding to
specific virion epitopes (42, 43). In this assay, virion particles
are captured onto microtiter wells to which the specific test
MAb is bound, and these captured virions are subsequently
quantitated using a separate p24 core antigen ELISA. Previous
studies have confirmed the antigenic selectivity of this assay
and its ability to specifically capture infectious virus particles
(7, 42, 43). We used this assay to extend our flow cytometric
findings to the Env complex of intact PI and TCLA virions. As
in these flow cytometric assays, HIVIG was used as a generic
capture reagent to normalize binding of each virus stock. Im-
portantly, MAb incubations in the virion capture format were
performed at 37°C.
The relative amount of PI and TCLA virus p24 captured in
this assay is shown in Fig. 5. In all cases, the PI virion was
efficiently captured by MAbs that were unable to neutralize the
PI virus. Where the nominal MAb epitope was conserved be-
tween the PI and TCLA Envs, the assay resulted in the isola-
tion of up to twofold-more PI virus than TCLA virus. Although
the basis for the greater capture of PI virus is unclear, the
finding was consistent between the two pairs of pedigreed
viruses. In the case of MAb 268-D, where the nominal epitope
is altered on the TCLA virus 320SI-C3.3, capture of this virus
was markedly reduced. The nominal epitope of MAb 257-D
differs from that of 320SI at a single site and from that of
320SI-C3.3 at one additional amino acid. Although the com-
mon difference does not appear to affect virus capture, the
additional amino acid change in the TCLA virus may be re-
sponsible for the reduction in 320SI-C3.3 binding. It is worth
noting that this reduction in binding was not apparent under
the saturating antibody conditions used in flow cytometry but is
perhaps reflected in the reduced neutralization sensitivity of
320SI-C3.3. These known immunochemical differences pro-
vide additional confirmation of the specificity of this assay. In
the absence of confounding local immunochemical differences,
MAb capture of the PI virion was at least as efficient as that of
the TCLA virion.
These virion capture ELISA findings clearly demonstrate
that MAbs are able to bind equally to the Env complex in both
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the TCLA and PI virus populations. These populations are,
however, heterodisperse and contain a majority of so-called
defective particles—virions which are unable to successfully
complete infection (30). To ascertain whether MAbs which
distinguish between PI and TCLA viruses by differential neu-
tralization bind comparably to infectious PI and TCLA virions,
we utilized MAb-coated magnetic beads to isolate virus and to
quantitate captured viral infectivity. Biotinylated MAb 50.1
was attached to streptavidin-coated magnetic beads (M-280
Dynabeads; Dynal) and incubated with virus stocks of either
168P or 168C. Magnetic streptavidin-coated beads which had
been preincubated with nonbiotinylated MAb 50.1 served as
specificity controls. Beads were subsequently washed exten-
sively and diluted onto U87-CD4-CXCR4 target cells. As
shown in Fig. 6, biotinylated MAb 50.1 was able to specifically
capture infectious virus from both the PI and TCLA virus
populations. In both cases and at either 4 or 37°C, approxi-
mately 3 to 5% of the initial viral infectivity was retained on the
MAb-coated magnetic beads. Little or no infectivity was re-
tained by control beads that had been mock incubated with
nonbiotinylated MAb 50.1. Previous studies by Nyambi et al.
(43) have also demonstrated MAb capture of infectious PI
virus by using the microtiter well format.
These virion capture findings clearly demonstrate that MAbs
are able to bind to the Env complex of both infectious neu-
tralization-resistant PI virions and infectious neutralization-
sensitive TCLA virions at 37°C and corroborate results ob-
tained from the flow cytometric analysis of a cell-associated
Env complex. Therefore, the differential sensitivity of PI and
TCLA viruses to neutralization does not derive from a simple
difference in initial MAb binding.
Flow cytometric analysis of MAb binding affinities. Not only
are the extents of initial MAb binding equal between PI and
TCLA Envs, but so are the affinities of MAb binding. To derive
dissociation constants (Kd) for the binding of anti-Env MAbs,
we varied the antibody concentration in the binding reaction
and used flow cytometry to determine relative MFC values.
These values are equivalent to the relative occupancy value (u)
modeled by Klasse and Moore (26). Thus, MFC 5 (A/Kd)/(1 1
A/Kd), where A is the concentration of free MAb. Under con-
ditions used in the binding assay, where MAb is in vast excess
of cell surface Env, A approximates the initial MAb concen-
tration, A0. One can thus approximate Kd by determining the
A0 at which the measured MFC is reduced to 50% of the
maximum (48, 55). Binding curves obtained using two V3 loop-
directed MAbs (50.1 and 447-52D) and cells expressing either
168P or 168C Env are shown in Fig. 7. Approximate Kd values
for MAb binding to cell-associated PI and TCLA Envs were
equal: 7 nM for MAb 50.1 and 3 nM for MAb 447-52D. At all
MAb concentrations tested, the ratio of PI and TCLA MFC
values remained constant, allowing further confirmation that
the Kd values for MAb binding to the PI and TCLA Envs were
approximately equal.
MAb binding to TCLA, but not PI, Env correlates with
neutralization. It is interesting to note that the binding curves
for the two V3-loop-directed MAbs shown in Fig. 7 approxi-
mate the curves of TCLA virus neutralization shown in Fig. 2A
FIG. 5. Relative capture of PI and TCLA virions. Virus stocks were
prepared from supernatants of acutely infected peripheral blood
mononuclear cells (PI virus) or H9 cells (TCLA virus). The virion
capture ELISA was performed as described by Nyambi and colleagues
(42). V3-loop-directed MAbs 58.2, 268-D, 257-D, and 447-52D were
bound to microtiter wells in 100 ml at a concentration of 10 mg/ml;
HIVIG was bound at 50 mg/ml. Virions were subsequently captured
from 100 ml containing 100 ng of p24 per ml. The amount of virion
captured by the specific MAbs is expressed as a percentage of that
captured by HIVIG, in order to normalize results across virus stocks.
For clarity, we show the relative capture of TCLA virion versus PI
virion as the ratio of the HIVIG-normalized percentages. In the ex-
periments shown, the underlying amounts of virion p24 captured by
HIVIG were as follows: 168P, 902 pg/ml; 168C, 927 pg/ml; 320SI, 370
pg/ml; and 320SI-C3.3, 257 pg/ml. The amounts of 168P and 320SI PI
virus captured by the MAbs were as follows, respectively: 58.2, 299 and
384 pg/ml; 268-D, 439 and 116 pg/ml; 257-D, 665 and 196 pg/ml; and
447-52D, 864 and 180 pg/ml. The relative capture of 168C and 168P is
shown in dark bars, and 320SI-C3.3 and 320SI in light bars. As calcu-
lable, correspondingly less TCLA virion was captured than PI virion. p,
320SI-C3.3 virions whose V3 loop sequence contains an alteration of
the nominal MAb epitope.
FIG. 6. MAb capture of infectious PI and TCLA virions. Virions
were captured from 168P and 168C virus stocks (dark and light sym-
bols, respectively) using streptavidin-coated M-280 Dynabeads to
which biotinylated MAb 50.1 had been bound. Infectivity retained by
the MAb was assessed by culturing U87-CD4-CXCR4 cells with the
extensively washed magnetic beads, and the numbers of infected cell
foci were determined as described in Materials and Methods. Incuba-
tions of virions with MAb-coated beads were at 4 or 37°C (circle and
square symbols), and retained infectivity is compared to that in the
initial virus stock used for capture (triangle symbols). Streptavidin-
coated beads that were incubated with nonbiotinylated MAb 50.1
(mock) served as specificity controls (data not plotted; all, #5 foci/
well).
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and D. In the case of the TCLA virus, binding appears to
correlate with, and presumably mediate, virus neutralization.
These findings are similar to the results of studies of MAb
binding to TCLA Envs and Env peptides (6, 48, 62) although,
as demonstrated above and by others (7, 43), MAb binding to
virions can clearly occur in the absence of even TCLA virus
neutralization (e.g., MAb F240). The unique aspect of the
present study, however, is that the PI Env complex can be
saturated with MAbs that effectively neutralize TCLA viruses,
but these saturating concentrations of MAb are not sufficient
to affect PI virus neutralization.
DISCUSSION
The remarkable dichotomy in neutralization sensitivity of PI
and TCLA viruses raises two related and fundamental ques-
tions: what are the mechanisms of antibody-mediated virus
neutralization, and how do these differ between PI and TCLA
viruses? In other words, by what mechanism do viruses with
Env complexes that differ at only 2 or 3 amino acids display
such strikingly different patterns of neutralization? Our results
clearly demonstrate that these differences in neutralization
sensitivity can exist without apparent differences in the initial
antibody binding event, and suggest that the differential con-
sequences of MAb binding reflect differences in the subse-
quent functioning of PI and TCLA Envs in mediating virus
fusion and entry.
Previous studies have examined the relationship between
MAb binding and the differential neutralization sensitivity of
PI and TCLA viruses, but conclusions have been discordant
and confounded by methodological limitations. In the present
work, we have revisited this question using a panel of well-
defined PI and TCLA viruses and three complementary tech-
niques to arrive at a more definitive conclusion. By using mo-
lecularly cloned Envs derived from pedigreed PI and TCLA
viruses that differ in a very limited number of amino acids, we
have reduced to a minimum any local immunochemical differ-
ences that may enter into cross-sectional studies of the genet-
ically diverse viruses used by others (4, 56, 57). Adventitious
differences arising in one pair of related PI and TCLA viruses
were excluded by comparison with a second pair of PI and
TCLA viruses. By using CD4-negative cells for Env expression,
we have circumvented concerns regarding MAb binding to
shed monomeric gp120 that may then be captured by CD4-
positive T cells (4, 54, 65, 68). Moreover, by assessing MAb
binding to both intact virions and to cell surface-expressed
Env, we have attempted to mitigate limitations inherent in
each of the methodologies. The concordance of results ob-
tained using cell surface-expressed Env and intact virion par-
ticles provides further support to our conclusions and the re-
spective methodologies.
We find that differential neutralization sensitivity of PI and
TCLA viruses can exist without demonstrable differences in
the extent or affinity of antibody binding. These findings echo
those of others who have also demonstrated MAb binding to
intact and infectious PI virions and cell-associated PI Env (42,
43, 56, 57, 68). Similarly, there have been reports of MAb
binding to TCLA viruses in the absence of a neutralizing out-
come (7, 43). What has been lacking in these analyses has been
the direct comparison between antigenically related neutral-
ization-resistant PI and neutralization-sensitive TCLA viruses.
Some of these earlier studies also report, as do we, MAb
binding to epitopes that have been hypothesized to be buried
within the Env complex (7, 42, 43). These observations raise
the possibility that the native, membrane-bound Env complex
may differ, structurally or dynamically, from the model derived
from immunological and structural analyses of soluble Env
molecules (gp120 and gp140) (27, 39, 66).
Our findings stand in apparent contradiction to those antic-
ipated by the prevalent model, which suggests that the differ-
ences in neutralization sensitivity of PI and TCLA viruses
reflect differences in the ability of antibodies to bind to the
respective Env complexes (36). This model proposes (i) that
adaptation to persistent growth in T-cell lines selects for viri-
ons that are able to rapidly bind and enter target cells, (ii) that
the structural and/or dynamic changes that facilitate binding to
cell receptors concomitantly expose critical neutralizing deter-
minants within the TCLA Env complex, (iii) that binding of
FIG. 7. Flow cytometric determination of the binding affinity of MAbs 50.1 and 447-52D to 168P and 168C Envs. In this experiment, co-
transfected COS-7 cells expressing GFP and either 168P Env (dark lines) or 168C Env (light lines) were stained using the indicated concentrations
of MAb 50.1 (A) or 447-52D (B). MFC values for MAb binding to GFP-positive cells were determined as described for Fig. 1 and 2. The percentage
of maximal binding was determined for each MAb dilution as the ratio of MFC values.
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antibody to the TCLA Env complex necessarily results in neu-
tralization (48, 49), and (iv) that the relative resistance of PI
viruses to neutralization reflects the inaccessibility of the PI
Env complex to antibody binding.
Since the initial discovery that PI viruses were resistant to
neutralization by gp120 vaccine sera that neutralize TCLA
viruses (cited in reference, 9), several alternative explanations
have been proposed, but none has been entirely satisfactory.
One might imagine that passage of the TCLA virus in the
absence of in vivo pressure from antibody may permit the Env
to divest itself of unnecessary shielding mechanisms and
thereby become more sensitive to neutralization. This expla-
nation is weakened, however, by findings that continued pas-
sage of PI viruses in permissive cells (primary T lymphocytes
and, for some isolates, MT4 cells) does not select for neutral-
ization sensitivity (16, 46). Alternatively, it has been suggested
that PI virions carry more Env spikes than TCLA virions and
that this increased spike density may result either in differential
shielding of critical PI Env determinants (34, 36, 44), or in an
increase in the amount of antibody needed to inactivate a
critical number of Env spikes (26). Other studies, however,
have not observed consistent differences in spike density (24,
65), and we found that our PI and TCLA virions contain
comparable ratios of gp120 Env to p24 Gag protein (Materials
and Methods; data not shown). If spike density is comparable
between PI and TCLA virions, one might still propose that PI
and TCLA virions differ in the minimal level of MAb binding
needed to affect neutralization (26). However in our studies, PI
viruses remain infectious at MAb concentrations that saturate
Env binding. With the discovery of HIV coreceptors, another
explanation for differential sensitivity to neutralization was
considered, that neutralization sensitivity of PI and TCLA
viruses might be related to differential coreceptor utilization
(CCR5 or CXCR4, respectively). Multiple studies, however,
argue against a role of this dichotomy in coreceptor use in
determining neutralization sensitivity (16, 28, 33, 61).
Some of the apparent contradictions between our present
findings and those anticipated by the prevalent model of
Moore and Ho (36) may derive from previous conclusions
from studies of antigenically dissimilar PI and TCLA viruses
and Envs (4, 36, 56, 57). Others may derive from generaliza-
tions to PI viruses of findings obtained using TCLA Envs and
their recombinant gp120 and gp140 molecules (35, 48, 54).
Whereas we agree with Parren et al. (48) that, among TCLA
viruses and their neutralizing MAbs, occupancy of sites on the
virion determines neutralization, we question the extrapolation
of these findings to PI viruses.
Ultimately, some of the discrepancies between studies may
be attributable to universal and insurmountable limits in the
ability to definitively correlate measures of MAb binding and
virus neutralization. For instance, all studies of MAb binding
to cell-associated gp120-gp41 Env complexes are confounded
by the presence of uncleaved, nonfunctional gp160 molecules,
and this situation is exacerbated in studies using highly express-
ing transfected cells in which the cell’s ability to proteolytically
process gp160 is overwhelmed. Although antigenic differences
between functional gp120-gp41 and nonfunctional gp160 Env
complexes have not been defined, these remain a theoretical
concern (47). In the one instance for which structural infor-
mation is available, the homologous proteolytic cleavage of the
influenza virus hemagglutinin (HA) precursor (designated
HA0) to mature HA1 and HA2 forms, it has been shown to
have only localized effects on HA structure (8). It is unlikely
that local structural changes induced by proteolytic cleavage of
the preassembled Env oligomer would extend to the broad
range of MAb specificities used in this work.
By contrast, little uncleaved gp160 is incorporated into virus
particles (reference 14 and data not shown). Therefore, con-
cerns arising from the presence of uncleaved gp160 molecules
are minimized in studies of MAb binding to intact virions (42,
43, 56). Such studies also incorporate the structural changes in
Env that may derive through interaction with virion core pro-
teins (15).
However, studies of MAb binding to intact virions suffer
from the inability to discriminate between MAb binding to
infectious virions and to the majority of defective virion parti-
cles (30). Thus, one can argue that binding measurements may
be unrelated to neutralization of infectious virions. It is largely
unknown, however, whether the majority of virions bear inher-
ently defective Env complexes or whether defectiveness re-
flects a stochastic outcome of attempted infection. Although
some virions may lack gp120 as a result of shedding, this
mechanism cannot account for the overwhelming bulk of de-
fective virions. Even if one focuses exclusively on MAb binding
to infectious particles, as we and others (43) have reported,
one cannot exclude the possibility that infectious virions are
captured via MAb binding to a defective Env spike. Ultimately,
virion stocks contain a range of Env spike densities and func-
tionality. All assays reflect averages within this heterodisperse
population, thus making direct comparisons between immuno-
chemical and structural measurements difficult.
This discussion is, of course, not to suggest that immuno-
chemical and functional studies of HIV Env are without merit.
Rather, we seek to examine the limits which apply variously to
all past and present studies.
If differences in MAb binding affinities do not determine
differences in the neutralization sensitivity of PI and TCLA
viruses, then what does? Although our equilibrium measure-
ments of binding affinity do not capture the underlying rate
constants, it is unlikely that the equal affinities we measure
result from compensating differences in on and off rates. Per-
haps PI and TCLA Envs assume different conformations or
quaternary structures on resting virions, such that initial anti-
body binding occurs with equal affinity but with different con-
sequences upon subsequent activation of Env. For instance,
antibody binding might lock the TCLA Env into a nonfunc-
tioning conformation, whereas the PI Env might be free to
bypass this localized perturbation. It is, however, unlikely that
these localized differences would be reflected in all MAb spec-
ificities examined in the present study. Alternatively, neutral-
izing MAbs might cross-link adjacent TCLA Env monomers,
whereas PI Env complexes might be configured so as to make
MAb bridging more difficult. Cross-linking, however, is not
required for TCLA virus neutralization (1, 53).
More likely, PI and TCLA Envs may differ in the subsequent
conformational changes and/or protein-protein interactions
that mediate Env function. We might speculate, for example,
that the energetics of receptor binding and subsequent gp120-
gp41 conformational changes may differ between PI and
TCLA viruses. In the case of PI viruses, these energetics may
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be sufficient to dislodge bound MAb during Env functioning.
Studies are underway to explore the retention of specific MAbs
during Env functioning (Trahey and Nunberg, unpublished).
Our findings focus attention on differences that arise subse-
quent to the initial antibody binding event. If the initial MAb
binding event is similar for TCLA and PI virions, then the
differential outcome of binding (neutralization or lack thereof)
must clearly arise through structural and mechanistic differ-
ences between the functioning TCLA and PI Envs. Thus, this
report directs future studies towards a more detailed exami-
nation of the process of Env-mediated binding, fusion, and
entry. Such efforts will shed light onto the mechanisms of virus
neutralization and may illuminate the structural basis for the
broadly neutralizing antibody response elicited by immunogens
comprising the functioning Env (29, 41). From these studies
may emerge novel strategies and targets for the development
of effective HIV vaccines and antiviral agents.
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